A new drug could change everything for children like seven-year-old Liliana, who has Prader-Willi syndrome, a rare genetic ...
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Soleno Therapeutics as the specialty pharmacy ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
Soleno Therapeutics today announced that the US FDA has approved VYKAT XR (diazoxide choline) extended-release tablets, for ...
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...
Soleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by ...